Neuphoria Therapeutics (NEUP) Assets (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Assets of $34.8 million for Q1 2026, up 13.34% year-over-year from $30.7 million in Q1 2025, and down 4.89% quarter-over-quarter from $36.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Assets (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Assets for 7 consecutive years, with $34.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 13.34% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $34.8 million (up 13.34% YoY), while the FY2025 annual figure was $28.6 million, up 3.4% from the prior year.
- Assets fell to $34.8 million in Q1 2026 per NEUP's latest filing, from $36.6 million in the prior quarter.
- Across five years, Assets topped out at $46.8 million in Q2 2022 and bottomed at $18.2 million in Q4 2024.
- Historically, Assets has averaged $30.2 million across 5 years, with a median of $28.7 million in 2025.
- Annual changes were most pronounced in 2023 — Assets tumbled 38.56% — and 2025, when it surged 101.44%.
- Neuphoria Therapeutics' Assets stood at $46.8 million in 2022, then tumbled by 38.56% to $28.7 million in 2023, then tumbled by 36.79% to $18.2 million in 2024, then jumped by 101.44% to $36.6 million in 2025, then decreased by 4.89% to $34.8 million in 2026.
- Business Quant data shows NEUP's Assets at $34.8 million in Q1 2026, $36.6 million in Q4 2025, and $27.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 34.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.81 Mn |
| Dec 31, 2025 | 36.60 Mn |
| Sep 30, 2025 | 27.34 Mn |
| Jun 30, 2025 | 28.59 Mn |
| Mar 31, 2025 | 30.71 Mn |
| Dec 31, 2024 | 18.17 Mn |
| Sep 30, 2024 | 22.92 Mn |
| Jun 30, 2024 | 27.65 Mn |
| Jun 30, 2023 | 28.74 Mn |
| Jun 30, 2022 | 46.78 Mn |
| Jun 30, 2021 | 41.79 Mn |
| Jun 30, 2020 | 715,830.75 |